Journey Medical Corporation reported financial results for the second quarter ended June 30, 2026. Total revenues increased 23% to $18.5 million from $15.0 million in the prior-year period, driven by Emrosi sales of $8.1 million and total prescriptions reaching approximately 36,000. The company achieved a GAAP net loss of $0.3 million, or $(0.01) per share, compared to a net loss of $3.8 million in the previous year. Selling, general and administrative expenses decreased by $1.0 million to $10.9 million due to reduced launch-related spending. At quarter-end, cash and cash equivalents stood at $25.6 million. Journey Medical Corporation is a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription products for dermatological conditions.